Nov 16, 2026CG Oncology bladder cancer immunotherapy cuts tumor recurrence risk by 68% in Phase 3CG Oncology reported its oncolytic immunotherapy met the primary endpoint of a late-stage trial in non-muscle invasive bladder cancer, reducing tumor recurrence risk by 68%.Nov 16, 2026·3 sources00
Jul 31, 2026FDA Advisory Committee Votes 10-3 in Favor of Replimune's RP1 Efficacy Data from Ignyte StudyThe FDA's Cellular, Tissue, and Gene Therapies Advisory Committee determined that efficacy data from Replimune's Ignyte study for RP1 is evaluable and clinically meaningful, voting 10 to 3 in favor.Jul 31, 2026·1 source00